Health Sciences Acquisitions Corp 2 (HSAQ)


Stock Price Forecast

Jan. 26, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Health Sciences Acquisitions Corp 2 chart...

About the Company

Health Sciences Acquisitions Corporation 2 is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The sponsor of the Company is HSAC 2 Holdings, LLC, an affiliate of RTW Investments, LP. HSAC 2 anticipates targeting companies domiciled in North America or Europe that are developing assets in the biopharmaceutical and medical technology sectors, which aligns with the Company's management team's experience in healthcare investing and drug development.

Employees

4

Exchange

NASDAQ

$3B

Total Revenue

4

Employees

$59M

Market Capitalization

-331.98

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $HSAQ News

Decoding Danaher Corp (DHR): A Strategic SWOT Insight

1d ago, source:

Threats: Intense competition and sensitivity to economic and geopolitical risks.

Buy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab Trials

1mon ago, source: Business Insider

The company was founded in 2018 and is headquartered in New York, NY. Read More on IMVT: Health Sciences Acquisitions Corporation Registered Shs NewsMORE Related Stocks Indices Commodities ...

Adagio Medical to go public in $113M deal with SPAC ARYA Sciences

2mon ago, source: Hosted on MSN

said Wednesday it would go public via a merger with ARYA Sciences Acquisition Corp. IV (NASDAQ:ARYD), giving the combined entity an enterprise value of $113 million. The transaction implies a post ...

ICON (ICLR) Gains From New Offerings, Strategic Acquisitions

7d ago, source: Zacks.com on MSN

ICON plc’s ICLR focus on Patient Access & Engagement strategy and favorable CRO industry trends are major tailwinds.

Chips 2.0 for biomanufacturing, and other big ideas from MassBio conference

1d ago, source:

Speakers at MassBio’s conference focused on how despite industry headwinds and global challenges, Massachusetts has remained ...

Business Acquisition: A Road To Success For Small Business Growth

10mon ago, source: Forbes

Acquisitions can help you efficiently break ... Growth through certification became Streisand's 2.0 version of The Mixx. "The Mixx's core competency is serving underrepresented communities ...

Baron Health Care Fund Q1 2024 Shareholder Letter

2d ago, source: Seeking Alpha

This compared with the Benchmark's weighted average market cap of $232.2 billion. We continue to invest in multiple secular ...

Danaher Corp (DHR) Q1 2024 Earnings: Mixed Results Amid Market Challenges

2d ago, source:

Outlook: Forecasts a mid-single-digit decline in non-GAAP core revenue year-over-year for Q2 2024 and a low-single-digit ...

Laboratory Corporation of America Holdings: Labcorp Announces 2024 First Quarter Results

13h ago, source: Finanznachrichten

Results from Continuing Operations for first quarter 2024 versus last year: Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% Diluted EPS: $2 ... Health in Massachusetts ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...